ro 4

Ro 4-6824 is a biochemical with immunosuppressive action.

Ro 48-8071 fumarate, an inhibitor of OSC (Oxidosqualene cyclase; IC50=6.5 nM), exhibits LDL (low-density lipoprotein) cholesterol-lowering activity.

Ro 41-3290, the desethylated derivative of Ro 41-3696, is a nonbenzodiazepine partial agonist at the benzodiazepine receptor.

Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (Kd: 16.5 and 64.4 nM, respectively).

RO 4938581 is an effective and selective agonist of GABAA α5 inverse (Ki: 4.6 nM for GABAA α5β3γ2a, and shows a lower affinity at α1β3γ2a, α2β3γ2a, α3β3γ2a (Ki, 174, 185, 80 nM, respectively)).

Ro 44-3888, the active component of sibrafiban, achieves predictable plasma concentrations when administered orally in its prodrug form, Ro 48-3657. Upon reaching a steady state after the second dose, Ro 44-3888 exhibits concentration-dependent inhibition of platelet aggregation and prolongs bleeding time. These findings suggest that Ro 44-3888 merits further evaluation, especially in patients at high risk of arterial thrombosis and those with acute coronary syndrome, due to its reliable absorption.

Oxidosqualene cyclase inhibitor

Ro 41-0960 is used as a reversible and orally-active COMT-inhibitor.

Ro 43-5054 is a small molecular, noncyclic peptidomimetic inhibitor.

Ro 41-1049 is a reversible, selective MAO-A inhibitor.

Ro 41-1879 is a catechol cephalosporin with antimicrobial activity.

Ro 41-5253 is an orally active RARα antagonist, ligand, and partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ. It exhibits antitumor activity, inhibits proliferation, and induces apoptosis in MCF-7 and ZR-75.1 estrogen receptor-positive breast cancer cells.

Ro 47-3359 is a topoisomerase II-targeted drugs with cytotoxic potential.

Ro 48-6791, a GABA receptor agonist, is used potentially for anesthesia.

Ro 48-8587 is a competitive antagonist of AMPA receptor.

Ro 46-2005 is a synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor, IC50: 220 nM).

Ro 47-1669 is a bioactive chemical.

RO 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist. RO 46-8443 displays up to 2000-fold selectivity for ETB receptors both in terms of binding inhibitory potency and functional inhibition.

(4R)-4-(3-Fluoro-2-methylphenyl)-4,5-dihydro-2-oxazolamin was active against TRACE AMINE ASSOCIATED RECEPTOR (TAAR 1) with an EC50 of 0.017 μM and could be used to study neurological disorders.

R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1 2 4 with Ki of 2 nM 3 nM 1 nM. It is less potent to CDK7 and GSK3α β, while inactive to other kinases. Phase 1.

Diclofensine (Ro 8-4650) is a monoamine reuptake inhibitor that blocks dopamine (IC50=0.74 nM), norepinephrine (IC50=2.3 nM), and 5-hydroxytryptophan (IC50=3.7 nM) in synaptosomes of the rat brain. dAURK-4 hydrochloride is an inhibitor of dopamine (IC50=0.74 nM), norepinephrine (IC50=2.3 nM) and 5-hydroxytryptophan (IC50=3.7 nM).

Sulfamethoxazole (STX 608) is a Sulfonamide Antimicrobial. The mechanism of action of sulfamethoxazole is as a Cytochrome P450 2C9 Inhibitor. The chemical classification of sulfamethoxazole is Sulfonamides.

Benserazide hydrochloride (Ro 4-4602) is a peripherally-acting L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor.

Sulfamethoxazole sodium (Ro 4-2130 sodium) is a sulfonamide bacteriostatic antibiotic.